Table 1.
Characteristics and outcomes of the study CDI patients
|
|
Mild n=41 |
Severe n=18 |
p-value |
|
Age, years |
64.9 (±6.28) 65 (62-69) |
79.28 (±5.32) 81 (76-82) |
<0.0001 |
|
Gender, Male |
23 (56.1%) |
9 (50%) |
0.779 |
|
Mortality, Yes |
6 (14.6%) |
11 (61.1%) |
0.001 |
|
Cirrhosis, Yes |
8 (19.5%) |
2 (11.1%) |
0.708 |
|
Hypertension, Yes |
23 (56.1%) |
16 (88.9%) |
0.017 |
|
Diabetes, Yes |
22 (53.7%) |
13 (72.2%) |
0.252 |
|
Cardiovascular disease, Yes |
18 (43.9%) |
13 (72.2%) |
0.053 |
|
Lung disease, Yes |
5 (12.2%) |
8 (44.4%) |
0.014 |
|
Renal failure, Yes |
13 (31.7%) |
12 (66.7%) |
0.021 |
|
Malignancy, Yes |
9 (22.0%) |
6 (33.3%) |
0.517 |
|
Intensive care unit, Yes |
4 (9.8%) |
18 (100%) |
<0.0001 |
|
Antibiotics<14 days, Yes |
33 (80.5%) |
18 (100%) |
0.092 |
|
Leucocytes |
13,477.24 (±2,428.69) 13,300 (11,750-15,250) |
22,305.00 (±4,737.61) 22,325 (18,688-25,445) |
<0.0001 |
|
Neutrophils |
81.36 (±8.66) 79.8 (78.5-88.55) |
95.89 (±2.65) 96.25 (94.88-98.2) |
<0.0001 |
|
Hemoglobin |
11.18 (±1.33) 11.1 (10.1-12.25) |
11.00 (±1.29) 11.15 (9.78-12.15) |
0.723 |
|
Hematocrit |
39.12 (±4.54) 41 (37.65-42.3) |
36.56 (±5.48) 38.15 (31.39-41.38) |
0.074 |
|
Thrombocytes |
198,279.02 (±81,413.0) 190,000 (160,500-218,450) |
181,833.33 (±38,097.78) 170,000 (152,000-197,250) |
0.370 |
|
Creatinine |
1.35 (±0.53) 1.32 (0.8-1.74) |
2.95 (±0.76) 3.18 (2.2-3.5) |
<0.0001 |
|
Urea |
91.44 (±42.25) 88 (58.5-117.5) |
210.11 (±75.2) 204 (143.5-262) |
<0.0001 |
|
Albumin |
3.4 (±0.33) 3.5 (3.2-3.6) |
2.65 (±0.32) 2.6 (2.4-2.83) |
<0.0001 |
|
CRP |
29.32 (±13.41) 26 (20.5-34) |
163.06 (±89.77) 129 (101-243) |
<0.0001 |
|
ATLAS |
3.39 (±1.24) 3 (2-4.5) |
7.33 (±0.77) 7 (7-8) |
<0.0001 |
|
Calprotectin (μg/g) |
217.92 (±106.05) 195.42 (131.12-298.59) |
629.16 (±254.59) 615.14 (403.62-784.4) |
<0.0001 |